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using the Matsui-Kitamura stent graft for acute
aortic emergencies in the descending thoracic
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Hiroshi Ohtake, MD,a Keiichi Kimura, MD,a Junichirou Sanada, MD,b Osamu Matsui, MD,b and
Go Watanabe, MD,a Kanazawa, Ishikawa, Japan
Objective: In recent years, thoracic endovascular aneurysm repair (TEVAR) has been attempted for acute aortic
emergencies (AAEs). However, the risk factors for achieving good results have not been identified. Besides focusing on
Acute Physiology and Chronic Health Evaluation (APACHE) II score as a general indicator of patient condition, we
analyzed both preoperative factors and intraoperative/postoperative factors. The purpose of this study was to identify
those factors affecting the results of TEVAR using our Matsui-Kitamura stent graft (MKSG) for AAEs involving
descending thoracic aortic aneurysm.
Methods:Between July 2000 and June 2008, a total of 32 patients (23men, 9 women) with AAEs underwent endovascular
repair. AAE was a result of aortic aneurysm rupture in 16 cases, rupture of penetrating atherosclerotic ulcer in 2 cases,
traumatic aortic injury in 9 cases, complicated type B dissection in 4 cases, and aortic infiltration of sarcoma in 1 case. Low
blood pressure in 6 patients, acute renal failure in 7 patients, anemia due to bleeding in 12 patients were found at the time
of operation. Urgent TEVAR using the MKSG was performed. Perioperative and long-term results for these patients
were investigated.
Results: The delivery and technical success rate for TEVAR using the MKSG, was 100%. Perioperative mortality was
12.5%, and 5-year survival rate was 71%. In both univariate andmultivariate analysis, the APACHE II score clarified a risk
factor. Among the various elements of an APACHE II score, age, hematocrit, and total score were identified as significant
factors. The mean of an APACHE II score was 9.5. Patients with an APACHE II score >10 showed significantly lower
5-year survival rates than patients with an APACHE II score <9.
Conclusions: Good results were obtained using TEVAR to treat AAEs with MKSGs, both perioperatively and during
medium-term follow-up. Evaluation of risk factors for TEVAR of AAEs showed the utility of APACHE II score
(particularly age, hematocrit, and total score) with a score >10 indicating high risk. (J Vasc Surg 2010;52:1464-70.)Since Dake et al1 reported the use of thoracic endovas-
cular aortic repair (TEVAR) for the descending thoracic
aorta, this procedure has been performed to treat a variety
of pathologies of the descending thoracic aorta. This part of
the aorta is anatomically easy to approach, and the results of
elective TEVAR are good both perioperatively and during
long-term follow-up.2,3 TEVAR shows a lower incidence
of serious postoperative complications such as paraplegia
and paralysis than conventional surgery, and has become a
trusted method of treatment for descending thoracic artery
disorders.4,5
Currently, however, TEVAR is under investigation as a
treatment for acute aortic emergencies (AAEs) such as
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1464aortic aneurysm rupture, aortic dissection, and aortic in-
jury. Despite gradual improvement, conventional surgery is
associated with high rates of both mortality and complica-
tions.6,7 In recent years, TEVAR has been attempted for
the treatment of AAEs, albeit on a small number of pa-
tients.8-11 The disorder underlying the AAE can reportedly
affect perioperative results,12 and in addition to the various
disorders that can cause an AAE, the overall condition of
the patient is also expected to vary greatly depending on the
amount of hemorrhage. Numerous factors may be involved
in the therapeutic results of TEVAR for AAEs, including
preoperative, intraoperative, and even postoperative fac-
tors. To assess the general condition of patients at the time
of presentation, we used Acute Physiology and Chronic
Health Evaluation (APACHE) II score to quantify age,
respiration, circulation, blood test findings, Glasgow coma
scale, and several chronic diseases. The APACHE II score
was proposed by Knaus et al13 in 1981 as a severity index
for patients admitted to intensive care units and was revised
in 1985, and represents a standard indicator of patient
status in emergency medicine.
In the present study, TEVAR was performed using the
Matsui-Kitamura stent graft (MKSG) that we developed.
In Japan, TEVAR was first performed using homemade
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TAG Thoracic Endoprosthesis, W. L. Gore and Associates,
Flagstaff, Ariz) became available in 2008 and was followed
by the TALENT (Talent Thoracic Stent Graft System,
Medtronic Vascular, Santa Rosa, Calif) in 2009. Under
these circumstances, we developed the MKSG that has
been used in limited Japanese institutions starting from
1999. This flexible stent graft does not apply excessive
radial force to the arterial wall and can be loaded into a
narrow sheath. We are currently applying the device in
clinical settings.13,14 The purpose of this study was to
elucidate factors affecting the results of TEVAR using our
MKSG for AAEs of descending thoracic aortic aneurysms.
MATERIALS AND METHODS
Indications. AAEs of the descending thoracic aorta
region are defined as conditions that require emergency
treatment, such as aortic aneurysm rupture, aortic injury,
and aortic dissection.15 Patients eligible for TEVAR have a
proximal landing zone of 20 mm at the site where the
stent graft will be deployed in the aorta, including the
origin of the left subclavian artery, and a distal landing zone
of 20 mm, as confirmed by preoperative computed to-
mography (CT).
Patient characteristics. Between July 2000 and June
2008, a total of 32 patients (23 men, 9 women) with AAEs
underwent endovascular repair. The present study included
patients with such symptoms as chest pain, lower back pain,
or shock, but did not include asymptomatic patients who
were diagnosed by diagnostic imaging. The 32 patients
constituted all patients who met the indications during this
period. Baseline characteristics of patients are given in
Table I. Mean age of the patients was 68.3  14.8 years
(range, 33-87 years). An AAE was a result of aortic aneu-
rysm rupture in 16 cases, rupture of penetrating atheroscle-
rotic ulcer (PAU) in 2 cases, traumatic aortic injury in 9
Table I. Patient characteristics
Variable
No. or
mean  SD
Age (years) 68.3  14.8
Gender (male:female) 23:9
Smoking 14
Diabetes mellitus 5
History of hypertension 24
Ischemic heart disease 6
Previous aortic surgery 1
Etiology
Traumatic 9
Rupture of atherosclerotic lesion 18
Aneurysm 16
Penetrating atherosclerotic ulcer 2
Complicated type B dissection 4
Sarcoma invasion 1
APACHE II score 9.5  4.3
Time from onset (hours) 55.9  33.2
APACHE, Acute Physiology and Chronic Health Evaluation.cases, complicated type B dissection in 4 cases, and massivehemoptysis by aortic infiltration of sarcoma in 1 case. Table
II shows each element of the preoperative APACHE II
score.
Endovascular repair. All patients routinely under-
went a pre-procedural, contrast-enhanced CT scan. Endo-
vascular repair was performed as swiftly as possible after
admission to the hospital. All procedures were performed
under the permission of Kanazawa University medical eth-
ics committee, and after written informed consent was
obtained from each patient.
Stent graft system. The stent graft that we used was
developed at our institution and has been used in clinical
settings since 1998. The use of this stent graft requires
approval from the ethical review board of each institution.
We have already reported on the structure of the MKSG
and initial clinical experiences in detail (Fig).16,17 The
MKSG is made from a single 0.30-mm to 0.40-mm diam-
eter nitinol wire (Memoalloy; Tokin, Tokyo, Japan) and
comprises a braided framework constructed from a single
wire. This framework allows expansion and contraction in
relation to aortic diameter, preventing excessive radial force
from being applied to areas with a small diameter.
The MKSG was covered with a woven graft made
of polyester fabric, then attached with 5-0 interrupted
polypropylene sutures. To suit differing curvatures of the
aorta, a straight MKSG and a curvedMKSG that bends in a
right angle have been made. MKSGs 36 mm in diameter
were deployed through an 18F J-shaped sheath (curved
Keller-Timmermans introducer sheath; Cook Diagnostic
and Interventional Products, Bloomington, Ind). Larger
devices (42 mm in diameter) required a 20F sheath. A
specially designed preloader-type introducer (Medikit, To-
kyo, Japan) was also used to load the device into the sheath.
With regard to stent graft selection, the diameter of the
stent graft was set to 120% of the proximal site landing
zone, and a curved stent graft was selected when the
proximal site landing zone was the aortic arch or proximal
descending aorta.
MKSGs were selected to exclude the aneurysm com-
pletely in cases of aortic aneurysm, to cover the rupture site
completely in cases of PAU, to cover the tear completely in
cases of traumatic aortic injury, and to cover the entry
completely in cases of acute type B dissection. In addition,
grafts were selected at sufficient length to ensure a 20-mm
landing zone on both proximal and distal sides. In patients
with a short proximal landing zone, MKSGs were used in
the expectation of sacrificing the left subclavian artery.
Procedures. Stent graft placements were performed in
an operating room with the patient under local or general
anesthesia and active coagulation time was maintained at
200 to 250 seconds.
After surgical exposure of the common femoral artery,
a 5F sheath (Medikit) was inserted into the femoral artery.
A 0.032-inch guidewire (Terumo, Tokyo, Japan) was in-
troduced and advanced across the aneurysm into the as-
cending aorta. The 5F angiographic catheter with cali-
brated markers was then placed over the guidewire for
aortography. After confirming the relationship between the
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ing the best working projection, a 0.035-inch Amplatz stiff
guidewire (Cook Diagnostic and Interventional Products)
was introduced into the ascending aorta. Transverse arteri-
otomy of the common femoral artery was performed, and
the delivery systemwas advanced into the target segment of
the aorta over the guidewire. Before deployment of the
stent graft, the systolic blood pressure was lowered to 90
mm Hg to prevent inadvertent downstream displacement
of the stent graft during delivery. The MKSG was deployed
under road-mapping guidance, immediately followed by
dilation with a large occlusion balloon (Boston Scientific/
Medi-tech, Natick, Mass). To check for adequate stent
graft expansion, postprocedural intravascular ultrasound
scan was used in all patients.
Follow-up. All patients were subjected to a strict
follow-up protocol. Whenever the bare segment of the
stent graft covered the orifice of the arch branches, anti-
Table II. Each element of the preoperative APACHE II s
Elements Score 0 Score 1 S
Age in years 3 1
History of severe organ insufficiency
or immunocompromised 27 —
Rectal temperature (Celsius) 25 7
Mean arterial pressure (mm Hg) 26 1
Heart rate (ventricular response) 26 2
Respiratory rate 23 11
Oxygenation 24 4
Arterial pH 25 3
Serum sodium 30 1
Serum potassium 31 0
Serum creatinine 25 3
Hematocrit 20 1
White blood cell count 30 2
15-Glasgow coma scale 21 6
Total
APACHE, Acute Physiology and Chronic Health Evaluation.
Fig. The Matsui-Kitamura stent graft.platelet medication was administered from 10 days postop-eratively. Clinical examination and imaging of the aorta by
contrast-enhanced CT were performed, and the diameter
of the aneurysm was measured before discharge, at
3-month, 6-month, and 12-month follow-ups, and then
annually thereafter.
Definitions and statistical analysis. Technical suc-
cess was defined as technically successful deployment of the
stent graft at the intended target location. All statistical
analyses were performed using SPSS software (version
16.0; SPSS, Chicago, Ill). Continuous variables are pre-
sented as mean 1 SD and range or median and range,
and categorical variables are given as frequencies and
percentages. Between the survival and aneurysm-related
death groups, clinical risk factors were subjected to
univariate analysis. Furthermore, Cox regression analysis
was performed for these factors. Between the survival
and aneurysm-related death groups, each element of
APACHE II scores was subjected to univariate analysis.
Kaplan-Meier non-parametric methods were used to gen-
erate estimates of survival. Kaplan-Meier survival estimates
using the log-rank test were used to compare patients with
high APACHE II scores (10) and patients with low
APACHE scores (9). Values of P  .05 were considered
statistically significant.
RESULTS
Procedural and perioperative results. Procedural
data are given in Table III. There were no intraoperative
deaths. Delivery and technical success were achieved in all
patients. Mean operating time was 106 minutes. MKSGs
with an average diameter of 32.4 mm and mean length of
coverage of 109 mm were deployed. An 18F or 20F sheath
was used in 84% and 16% of patients, respectively. No injury
or endoleaks involving the access route were observed. The
left subclavian artery was sacrificed in 3 patients. Perioper-
ative mortality was 12.5% (5 aneurysm-related death cases).
These 5 patients died perioperatively, comprising 2 cases by
Score 3 Score 4 Score 5 Score 6 Mean  SD
6 0 11 11 4.38  1.91
— — 5 — 0.78  1.84
0 0 — — 0.22  0.42
0 0 — — 0.50  1.05
0 0 — — 0.31  0.69
0 0 — — 0.34  0.48
1 2 — — 0.53  1.14
0 1 — — 0.41  0.91
0 0 — — 0.09  0.39
1 0 — — 0.09  0.53
2 1 — — 0.47  1.05
1 0 — — 0.75  1.02
0 0 — — 0.06  0.25
2 0 — — 0.56  0.91
9.50  4.27core
core 2
0
—
0
5
4
0
1
3
1
0
1
10
0
3re-rupture, 2 cases by respiratory failure, and 1 case of death
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unknown. A postmortem examination was performed on 1
patient, showing hemorrhage in the left pleural cavity, but
no clear MKSG migration, and no aortic damage.
Mid-term and long-term outcomes. During a me-
dian follow-up of 30.8 months (range, 0-102 months), all
stent grafts remained patent without evidence of migration,
twisting, or fracture. No more aneurysm-related death
cases occurred during the following period. Complete em-
bolization of aneurysms was achieved in all patients other
than the 5 who died during the perioperative period. The
only case in which additional stent graft insertion was
required was the patient with sarcoma, in whom re-inter-
vention was performed after 3 months to treat infiltration
of the sarcoma into the aorta. Overall survival rates were
78.1  0.7% at 1 year, 78.1  0.7% at 3 years, and 71.0 
9.5% at 5 years. Deaths during long-term follow-up com-
prised 1 case each of death due to heart failure, respiratory
failure, cerebral infarction, and cancer.
Risk factor analysis. The univariate risk factor analysis
showed that preoperative ischemic heart disease and an
APACHE II score were significant risk factors (P  .05;
Table IV). Of the various elements of APACHE II score,
age, hematocrit, and total score were risk factors (Table V).
Cox regression analysis showed that only an APACHE II
Table III. Procedural data
Anesthesia
Local 15
General 17
Access route
Via femoral artery 31
Via the conduit of the aorta 1
Simultaneous surgery
Axillo-axillary bypass 3
AAA surgery 1
MKSG
Size of the sheath (18F:20F ) 27:5
Straight vs curved 12:15
Diameter (mm) 32.1  2.5
Covered length (mm) 118  21.5
Mean operation time (minutes) 106.1  39.6
Amount of blood transfusion (mL) 487.5  209.1
Perioperative mortality and complications
Mortality
Re-rupture 2
Respiratory failure 2
Unknown 1
Complications
Access route injury 0
Surgical conversion 0
Intimal injury 0
Major endoleaks 0
Neurological
Minor stroke 3
Paraplegia 0
Paralysis 0
Renal failure 1
Long-term ventilation 1
AAA, Abdominal aortic aneurysm; MKSG, Matsui-Kitamura stent graft;
min., minutes.score was a risk factor (Table VI). Themean of APACHE IIscore was 9.5. When we categorized patients into 2 groups
according to APACHE II score (10 vs 9), a significant
difference (P .037) in the survival rate was seen between
patients with postoperative intimal injury and those with-
out (94.4  5.4% vs 57.1  13.2% at 1 year, 94.4  5.4%
vs 57.1  13.2% at 3 years, and 78.7  15.1% vs 57.1 
13.2% at 5 years; P  .05).
DISCUSSION
In the present study, perioperative mortality and 5-year
survival rates for TEVAR using the MKSG for AAE were
12.5% and 71%, respectively. These results were compatible
to those in previous reports of TEVAR for AAE.9,18 In
particular, delivery was possible using a narrow sheath (20F
or narrower, 18F in 84%), and the absence of access route
damage was a major advantage of the MKSG system. In
both univariate and multivariate analyses, an APACHE II
score was clarified as a risk factor. APACHE II score anal-
yses showed that age and low hematocrit due to hemor-
rhage are risk factors. In addition, with regard to long-term
survival, the results suggest that an APACHE II score is the
only significant risk factor and is a predictor of outcomes.
Mean APACHE II score was 9.5, and patients with a score
10 showed a significantly lower 5-year survival rate than
those with a score 9, so a score 10 was regarded as
indicating high risk. None of the underlying disorders
constituted a significant risk factor, but atherosclerotic
disorders tended to show much higher risk than traumatic
aortic injury, suggesting that rupture of an aortic aneurysm
or PAU may be more serious.
The use of TEVAR for AAEs, including appropriate
indications, remains a challenging field, and few reports
have described around 30 cases compared with reports of
open surgery.9,18 We also began stent graft insertion for
thoracic aortic aneurysms in the year 2000 and have clinical
experience with approximately 200 patients, but these in-
clude only 32 cases of AAEs. We established solely anatom-
ical conditions for treatment indications that patients
should have: a proximal landing zone 20 mm, including
the origin of the left subclavian artery; and a distal landing
zone 20 mm. We chose to perform open surgery on
patients in whom a sufficient landing zone could not be
ensured. These conditions were the same as those for
non-AAE descending aortic aneurysms in terms of both
landing zone and MKSG diameter.16,17 Three sudden
deaths were observed during the perioperative period, and
type I endoleaks (endoleaks that could have been prevented
with a longer landing zone) could not be definitively ruled
out. However, with TEVAR, a longer landing zone is ideal,
and the landing zone should be as long as possible in the
treatment of an AAE.
Both delivery and technical success rates were 100%.
Neither a type I nor type II endoleak was observed in any
patient during intraoperative angiography. The main cause
of failure in the use of TEVAR for AAE is damage to the
access route caused by the device,19 which reportedly oc-
curs in 3% to 15% of patients.18,20 This is due to factors
such as aortic collapse because the patient is in shock, or the
rovasc
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arteries in atherosclerotic disorders. We have developed the
MKSG, a stent graft of up to 36 mm in diameter capable of
delivery at 18F, and achieved safe delivery in all cases in the
present series with no damage to the access route via a
femoral artery approach. In addition, no intraoperative
aortic injury was seen in the neighborhood of the rupture
site, and no complications caused by the procedure were
observed. The use of a range of different devices has been
reported, but the MKSG, which can be fitted with a smaller
Table IV. Univariate analysis of clinical risk factors
Clinical risk factor
Survival
(n  2
Categorical data
Gender (male:female) 19:8
Smoking 11
Diabetes mellitus 4
Hypertension 19
IHD 3
CVD 2
Non-thoracic trauma 5
Underlying disorder
Trauma 9
Atherosclerotic lesion 13
Complicated type B dissection 4
Tumor 1
Postoperative complications 5
Non-categorical data
Time from onset (hours) 28.3 
APACHE II score 8.4 
Operation time (minutes) 97.4 
Blood transfusion (mL) 481.5  2
Length of coverage by MKSG (cm) 120.5  2
APACHE, Acute Physiology and Chronic Health Evaluation; CVD, cereb
Matsui-Kitamura stent graft.
Table V. Univariate analysis of each element of the
preoperative APACHE II score
Elements
Survival
group
(n  27)
Procedure-
related death
group (n  5)
P
value
Age in years 4.15  2.00 5.60  0.55 .00
History of severe organ
insufficiency or
immunocompromised 0.74  1.81 1.00  2.24 .78
Rectal temperature 0.19  0.40 0.40  0.55 .30
Mean arterial pressure 0.52  1.09 0.40  0.89 .82
Heart rate 0.26  0.66 0.60  0.89 .32
Respiratory rate 0.37  0.49 0.20  0.45 .48
Oxygenation 0.37  0.97 1.40  1.67 .61
Arterial pH 0.22  0.58 1.40  1.67 .19
Serum sodium 0.11  0.42 0.00  0.00 .57
Serum potassium 0.00  0.00 0.60  1.34 .37
Serum creatinine 0.33  1.00 1.20  1.10 .09
Hematocrit 0.56  0.89 1.80  1.10 .01
White blood cell count 0.04  0.89 0.20  0.45 .47
15-Glasgow coma scale 0.44  0.89 1.20  0.84 .09
Total 8.30  3.12 16.00  3.94 .00
APACHE, Acute Physiology and Chronic Health Evaluation.size sheath, is regarded as useful for AAEs.To minimize perioperative complications, we were
careful to maintain optimum blood pressure during surgery
as protection for the spinal cord. Active coagulation time
was set at a maximum of 180 to 200 seconds to prevent
hemorrhage as much as possible, and some patients were
not administered heparin. Fortunately, neurological com-
plications of paraplegia and paralysis did not occur in this
series. Cerebrospinal fluid drainage is not easy to perform
for the patient in shock, so maintaining blood pressure may
be even more important. In addition, re-intervention was
not performed in any patient other than a single case in
which the aneurysm diameter increased due to cancer
growth during long-term follow-up, and no device-related
complications were encountered during the observation
period. However, late complications are said to increase
beyond 5 years postoperatively, and we intend to continue
careful observation using CT scans in the future.
Disorders that can cause AAEs include aortic injury,
aortic rupture, and acute or chronic dissection. The peri-
operative mortality of TEVAR for AAEs resulting from
aortic injury has been reported as around 2%.10 Rates of
around 10% for aortic rupture21,22 and around 15% for type
B dissection21 have been described somewhat higher than
the rate for aortic injury. In the present study, however, the
only risk factor found was an APACHE II score on hospital
arrival, with patients showing scores 10 having signifi-
cantly worse prognosis. An APACHE II score is widely
used in emergency medicine and intensive care as an index
for determining the patient’s general condition, including
age and underlying disorder.13 As all disorders caused by
AAEs result in a swift deterioration in patient conditions as
a result of hemorrhage, overall assessment of the general
Procedure-related death
group (n  5) P value
4:1 .66
3 .43
1 .77
5 .16
3 .01
0 .53
0 .30
0
5
0
0
0 .30
31.6  36.9 .84
16.0  3.9 .00
134.0  62.0 .06
520.0  178.9 .71
106.0  16.0 .28
ular disease; h, hours; IHD, ischemic heart disease; min., minutes; MKSG,group
7)
33.2
3.2
32.6
16.7
8.3condition on arrival at the hospital can be expected to
e inter
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score factor analysis clarified age, hematocrit, and total
score as risk factors. In this study, the time between onset
and hospital arrival was not identified as a risk factor. This
was regarded as being influenced by the fact that some
patients were under observation at a community hospital
because their hemodynamic status was stable. We believe
that an important treatment strategy for minimizing the
number of high-risk patients with scores 10 is to prevent
general conditions from deteriorating between AAE onset
and arrival at a hospital by performing stent graft insertion
as swiftly as possible.
Limitations. The present study was limited by the
relatively low number of patients treated. As a result, no
definitive predictors could be identified. Because the
MKSG that we developed is not a commercially available
device, use of the device at institutions other than our own
is currently difficult. In addition, this was not a randomized
controlled trial. Instead, we reported our mid-term experi-
ence with a median follow-up of 30.8 months. Long-term
follow-up studies are necessary to assess the durability and
effectiveness of TEVAR for AAEs. Causes of perioperative
mortality were sudden death, multiple organ failure, and
respiratory failure. Determination of a final judgment as to
whether the sudden deaths were caused by the general
condition of the patient or developed as a result of TEVAR
technical failure was not possible. In the 2 patients for
whom thoracic radiographs and CT scans could be ob-
tained, no major migration of the MKSG or dissection was
observed. In the future, therapeutic results should be im-
proved by more detailed analysis of the causes of perioper-
Table VI. Cox regression analysis of clinical risk factors
Factor
No. or mean
value
Categorical data
Sex (male:female) 23:9
Smoking 17
Diabetes mellitus 4
Hypertension 24
IHD 6
CVD 2
Non-thoracic trauma 16
Underlying disorder
Trauma 9
Atherosclerotic lesion 18
Complicated type B dissection 4
Tumor 1
Postoperative complications 4
Non-categorical data
Time from onset (hours) 28.8
APACHE II score 9.6
Operation time (minutes) 103.1
Blood transfusion (mL) 487.5
Length of coverage by MKSG (cm) 118.2
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidenc
min., minutes; MKSG, Matsui-Kitamura stent graft.ative death.CONCLUSIONS
Good results were obtained using TEVAR with
MKSGs for AAEs, both perioperatively and during medi-
um-term follow-up. The lack of access route damage was a
major advantage of the MKSG system. Evaluation of risk
factors for TEVAR of AAEs showed the utility of an
APACHE II score (particularly age, hematocrit, and total
score) with a score 10 indicating high risk. This study
identified an APACHE II score as the only statistically
significant risk factor, representing a predictor of outcomes.
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